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Adverse Effects of FK 506 Overdosage After Liver Transplantation 
M. Alessiani, U. Cillo, J.J. Fung, W. Irish, K. Abu-Elmagd, A. Jain, S. Takaya, D. Van Thiel, and T.E. Starzi 
PK 506 and cyclosporine (CyA) are not chemically 
related and have different cytosolic binding sites. 1.2 
However. it was noted almost immediately after FK 506 
was introduced clinically that its toxicity profile was sim-
ilar to Cy A. 3-, The principal side effects of nephrotoxi-
cityI~ diabetogenicity,1·8 and neurotoxicity9.IO have 
been reponed individually. However. we win present here 
the full range of these and other adverse reactions together 
in the first 370 consecutive liver recipients who were 
entered into the Pittsburgh FK 506 study during 1989 and 
1990. This case accrual was during a learning curve in 
which the daily induction doses were two or three times 
greater than those presently recommended. Consequently. 
a unique and unintended opportunity existed for overdose 
toxicology studies. 
METHODS 
Case Material 
The 370 consecutive adult patients received 417 liver transplants 
between August 1989 and December 1990. All patients were 
undergoing primary transplantation when they entered the study. 
Because older age was not a negative factor for candidacy. 76 
(20.5%) of the 370 patients were 60 years or older. of whom many 
had been declined for treatment elsewhere. Mean age was 47.0 :: 
12.7 years (range 15 to 75). The indications for liver transplanta-
tion are summarized in Table I. Parencbyma! liver disease. to 
which postnecrotic and alcoholic cirrhosis were the largest con-
tributors. accounted for 64.6% of the cases. Cholestatic diseases. 
for which the liver replacement operation tends to be technically 
easier. accounted for only 19.2% of the total. 
The urgency for transplantation for the majority of the candi· 
dates was high as defined by the United Network for Organ 
Sharing (UNOS) criteria that existed at the time (Table I): status 
1. at home. functioning without nursing care (4 patients); status 2. 
recurrently hospital-bound (126 patients); stalus 3 and 4. leu-
bound with 4 signifying ventilalor dependence (228 patients); and 
UNOStat. patients with fulminant hepatic failure. need for reo 
transplantation. or tenninal condition (III patients). Forty-one 
(11.1%) of these 370 patients required retransplantation; 35 had a 
second transplant. and 6 had 2 additional grafts. All of the detailed 
analyses were based on foUow-ups until July 15. 1991. At this 
time. the median duration of foUow-up was 12.2 months with a 
range of 6 to 23 months. Further. more limited analyses. including 
patient and graft survival plus ultimate renal function. were 
provided to July I. 1992. with foUow-ups of 18 to 35 months. 
Immunosuppression 
FK 506. The study was carried out in a developmental period 
when two or three times the dose of FK 506 was used for 
induction as is our current practice. An initial group of 196 
patients (53% of the total) was treated with intravenous doses of 
FK 506 infused at a dose of 0.075 mgtq over a 4-hour period and 
repeated every 12 hours. When the patients were able to eat. the 
intravenous FK .506 was contiDued for at least 1 day in an overlap 
Table 1. Cha~ of the Plltlent p~ TheIr 
01-. and the s.v.rtty of the CllnJQI Condition Before the 
UwrT,.,....,. 
Patient population 
No. patients 
No. grafts 
No. 1 re-OL Tx 
No. 2 re-OL Tx 
Age (y) 
Sex (MIF) 
Disease categories [no. cases ("10)1 
Nonalcoholic cirrhosis 
Alcoholic cirrhosis 
Cholastatic disease 
Tumor 
Fulminant failure 
Miscellaneous 
UNOS score [no. casas ("10)] 
1 
2 
3 
4 
UNOSTAT 
370 
417 
41 
6 
47:t 12 
221n49 
146 (39.5%) 
93 (25.1%) 
71 (19.2%) 
27 (7.3"10) 
12 (3.2"10) 
21 (5.7"10) 
4 (1.1%) 
27(7.3%) 
128 (34%) 
102(27.5%) 
111 (30%) 
period. while an oral dose of 0.15 mglkg was begun every 12 
hours. 
The next group of 174 patients received the same starting daily 
dose of FK 506 (0.15 mglkg), but as a continuous intravenous 
infusion rather than in 4-hour bolus every 12 hours. The conver· 
sion from intravenous to oral therapy was made without any 
overlap en route. The phannacokinetic and other differences with 
the two different regimens have been reponed by Abu-Elmagd et 
aI." 
Plasma trough levels of FK 506 were determined with an 
enzyme-linked immunoassay technique developed by Tamura et 
aI. 12 However. routine services and rapid turnaround for results 
were not available until the spring of 1990. Thus. the principal 
value of these results was to explain what already had transpired 
rather than to guide dosage. Toward the end of the trial. trough 
plasma FK .506 levels typically were determined twice weekly or, 
in comp1ic:ated cases. more often. By this time. dose adjustments 
during both the intravenous or the oral administration of the drug 
were dictated by plasma trough FK 506 levels. the presence of an 
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ADVERSE EFFECTS OF FK 506 
advenc drug reaction with special emphasis on neurotoxicity and 
nephrotoxicity. and the function of the graft. 
The crucial influence of hepatic graft function on FK 506 
metabolism and the develo"ment of adverse drug reactions was 
quickly leamed. Il•14 and by the end of the study. the recom-
mended standard treatment was to maintain an o"timaI plasma 
trough level between 0.5 and 2.0 ngimL. Higher doses (or plasma 
concentrations) of FK S06 were well tolerated if graft function was 
good. but when liver function was substandard. toxicity was 
anticipated even after major downward adjustments of the FK 506 
dose had been made. 
Other I mmufIOIuppress;'I'e Drugs. One gnun of solumedrol was 
administered intravenously in the operating room after graft 
reperfusion. A daily dose of 20 mg of prednisone was started and 
reduced in I or 2 weeks in the absence of rejection. Thereafter. 
prednisone was weaned and frequendy discontinued. In addition. 
the first 58 patients were given a 5-day prednisone "burst" 
beginning at 200 mgld for the first postoperative day. with reduc-
tions of 40 mgld until 20 mg/d was reached on the sixth day. 
When rejection supervened. it was treated with an increased 
maintenance dose of FK 506 if possible wllhout toxicity. and a 
single I-g bolus of either methylprednisolone or hydrocortisone. If 
the response to this fonn of treatment was unsatisfactory. a 3- to 
5-day course of OKT3 (5 or usually 10 mg/d) was administered and 
followed if necessary by augmented steroid doses. In a few cases 
in which this therapy failed. azathioprine was added to the FK 506 
plus prednisone regimen. 
Definitions of Nephrotoxicity 
Early Onset: A rise in the serum creatinine> 3.0 mgldL within the 
first 30 postoperative days after starting from a normal pretrans-
plant level. 
Late onset: A rise in the serum creatinine level >2.0 mgldL 
occurring after 30 postoperative days (isolated late onset) when 
starting from a normal pretransplant level or after an episode of 
early onset nephrotoxicity as defined above followed by recovery 
to a normal baseline (early plus late onset). 
Resistant: A serum creatinine level >2.0 mgldL that failed to 
recover to the pretransplant level after either early or late onset 
ne"hrotoxicityand persisted until the time of death or the end date 
of the study. 
Pretranspiant renal dysfunction: A pretransplant serum creati-
nine >2.0 mgldL and/or requirement for preoperative dialysis. 
Other Toxicity Definitions 
Hypenension: An arterial blood pressure elevation above 160 mm 
Hg systolic or 100 mm Hg diastolic for more than 2 months in a 
previously nonnotensive patient. or a need for antihypertensive 
drugs for any 6O-day period to control hypertension regardless of 
the measured blood pressure. 
Hyperkaiemill: A serum potassium level >5.3 meqlL or the 
need for a potassium-reducing aaent. such as sodium polystyrene 
sulfonate (Kay-exa1ate) or a synthetic mineral corticoid drug 
(Aorinet). 
Neurotoxicity: An acute severe neurological event (coma. de-
lirium. dysanhria. and seizures) not related to any other well-
defined cause. 
Type I Diabetes Mellitus: A requirement for insulin therapy for 
more than 30 days to maintain a fasting blood sugar level in the 
normal range. The onset of insulin dependence was classified 
"early" within the first 30 days and "late" thereafter. 
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Statistical Analyses 
629 
36 
Dilferences in means were assessed using the standard tw()o 
sample t test. while differences in proportions were assessed by 
the Pearson's chi·square test of association. The Wilcoxon Rank 
Sum test. a nonparametric equivalent to the standard two-sample 
t test. was used for highly skewed data. All tests were twCMailed. 
A P-value of less than .05 was considered statistically siguificant. 
Patient survival was calculated from the date of orthotopic liver 
transplantation until death. and primary graft survival from the 
date of primary liver transplantation until retransplantatioll or 
patient death. Survival curves were generated using the Kaplan-
Meier (product-limit) method. 
RESULTS 
Patient and Graft Survival 
Although the toxicity study was completed on July I. 1991. 
with a follow-up of 6 to 23 months. the actuarial patient 
and graft survival in ail cases was obtained to July I. 1992. 
for an 18- to 35-month follow-up. The actuarial 6-. 12-. and 
IS-month graft survival was 81%. 77%. and 75%, respec-
tively. The patient survival at these times was 88%,85%, 
and 82% (Fig 1). 
Nephrotoxicity 
Pretranspiant Renal Dysfunction. Of the 370 pabcnts, 
31 had pretransplant renal dysfunction (Fig 2). In 23, this 
was severe enough to require preoperative dialysis. Six 
(26%) of these 23 recipients died postoperatively while on 
dialysis; 3 others never recovered kidney function and 
were being dialysed at the closing date of the study, 
whereas the remaining 14 patients became dialysis-inde-
pendent after a median time of 34 days posttransplanta-
tion. In 10 of this last 14. renal function rewmed to normal. 
Of the other 8 patients with pretransplant renal failure. 3 
went on to postoperative dialysis which continued until the 
death of I. but was of brief duration in the other 2. One of 
the remaining S recovered fully, but the other 4 still had 
renal function abnormalities at the close of the study. 
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Fig 2. Summary of the incidence of nephropathy: a total of 54% 
of the patients developed nephropathy after the transplant In 20% 
of cases, the nephropathy became chronic (see Fig 4). 
Early Onset Nephrotoxicity. Of the remaining 339 pa-
tients, 137 (40.4%) experienced early onset nephrotoxicity 
(Fig 2). In 74 (21.8%), the onset of the nephrotoxicity 
seemed related solely to the usc of FK 506 and was 
correlated with significantly higher levels of plasma FK 
506 than in the nontoxic cohort (Fig 3). In the remaining 63 
(18.6%), other potentially nephrotoxic factors played a 
potentially important role: (1) nephrotoxic drugs (princi-
pally aminoglycoside antibiotics); (2) prolonged and diffi-
cult surgical procedure; (3) the need for retransplantation; 
(4) one or more episodes of severe hypotension or cardiac 
arrest: and (5) severe hepatic dysfunction. An elevated FK 
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FIg 3. FK 5081roUgh plasma levels at peek SCr during the first 
30 days post'()LTx: patienI8 with earty onset neptlropa1hy (FK-
dependent or with other COIICDIIIMt "....'*»dc fIM*n, VI 
patients without nephropathy. The dHraMce is statiIIIcIIIIy aignif-
icant. 
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506 level usually was found when one or more ofthcse five 
cofactors were present (Fig 3). 
The characteristics of the patients with and without 
concomitant nephrotoxic factors arc shown in Table 2 and 
Fig 3. Those exposed to nephrotoxic factors other than FK 
506 had a significantly greater need for dialysis (P < .(01), 
a higher death rate during the period of early onset renal 
dysfunction (P < .0001), longer duration of early onset 
kidney failure. and poorer rate of renal recovery. How-
ever, the subsequcnt incidence oflatc onset nephrotoxicity 
was greater in patients with pure FK 506 toxicity. Sixty-
eight of the 137 patients with early onset nephrotoxicity 
had complete recovery. 
Persistent Nephrotoxicity. Amongst the 137liver recip-
ients who developed early onset nephrotoxicity, there 
were 10 (6 in the FK-dependent group, 4 in the group with 
other concomitant factors, whose renal dysfunction was 
remarkably longer (more than ISO days) than in the other 
127 patients (Fig 2). This was defined as "persistent." One 
of these 10 patients died while still nephrotoxic. In 7, the 
nephrotoxicity became resistant (see below) and only 2 
patients recovered completely. Three of these 7 patients 
became dialysis-dependent. 
Late Onset Nephrotoxicity. After an initial period of 
seemingly complete recovery, 59 of the 137 patients with 
early onset nephrotoxicity had another episode of 
nepbropathy sometime after 30 days. Added to the 10 
patients with persistent nephropathy, and to these 59, were 
an additional 63 patients who developed de novo late onset 
ncpbrotoxicity (Fig 2). Although no statistical dift'erenccs 
between the recurrent (n = 59) and late onset groups (n = 
63) were found (Table 3), the trend was for patients with 
early onset nephrotoxicity to develop late nephropathy 
earlier and at a lower FK 506 level. Sixty-seven of the 122 
patients with de novo or recurrent late onset nephropathy 
never recovered to their baseline level of kidney function 
and were defined as having resistant nephrotoxicity. 
la18 NeptvopaItic liability 
In-Study Period. When the study was concluded in July 
1991, 200 patients from the total of 339 experienced a 
ncpbrotoxic episode (137 early onset. 63 de novo late 
onset); 166 were still alive (83%). Seventy-four (22% of the 
0ri8iDa1339) developed resistant nephrotoxicity, 7 after an 
early onset episode that was persistent. and 67 after a late 
onset. Complete recovery was sccn in the other 92 within 
the time frame of the study. 
At 6 months follow-up, 302 (89.1%) of the 339 patients 
entered were alive. Of these 302 patients. 76 were neph-
rotoxic. of whom 23 recovered to achieve a normal base-
line ercatinine; 6 died while still in renal failure; and 47 still 
have some evidence of nephrotoxicity. 
At 12 months follow-up, 293 (86.6%) survived and 71 
(24.2%) were nephrotoxic as defined by serum creatinine 
(sCr) >2 mgldL (2.93 : 1.9 (SD) mgldL). 'fbrouIbout the 
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T ... 2. Incldellc" FK 501 Trough ,...... LeveIa, GeMnI ~ and OUtcome of the EerIy Oneet Neptnpdlf 
or.. 
ch~ Faca. PV" 
No. patients (%) 74(21.8%' 63(18.8%, NS 
FK 506 levels (nglmL, 
At start onset 5.8: 5.0 5.7: 5.1 NS 
At peeK SCr 4.3: 3.7 5.0: 5.2 NS 
At and onset 1.6: 1.6 2.4: 2.7 NS 
Peak SCI during onset (rngIdL) _ 4.4: 1.5 4.5: 1.4 NS 
Medlen time of occumtnee (a after'OL Tx) 5.5 5 NS 
Medlen duration of onset (a) 10 14 NS 
No. patientS requiring aialy8ia 20(27%) 37 (59%) P< .001 
Outcome {no. patianIS (%)) 
Deaths during onset 2 (2.7%) 18 (28.60/0) P< .001 
Late onset without recovery 6 (8.1%, 4 (6.3'Yo) NS 
Late onset after recovery 36(48.6%) 23 (36.5%, NS 
Complete recovery 30 (40.6%) 18 (28.8%) NS 
first 6 months. the percentage of nephrotoxic patients 
increased. but after it declined steadily (Fig 4). 
Late Follow-up. By July 1992, with follow-up of 18 to 35 
months. 273 (80.5%) survived and 56 (20.5%) were neph-
rotoxic. Their mean SCr was 2.62 ± 1.22. The mean 
plasma levels of FK 506 in these patients was 0.77 ± 0.64, 
which is in the putative nontoxic range. 
Dialysis Requirements 
Seventy-five (22.1%) of the 339 patients required dialysis 
(Table 4), 57 within 30 days. Recovery usually was asso-
ciated with a reduction in the FK 506 level. In cases with 
nephrotoxic cofactors other than FK 506, recovery oc-
curred even when the FK level remained above the 
acceptable therapeutic range (2.3 nglmL) , but in this 
high-risk group, the duration of the required dialysis was 
greater. 
T ... 3. InctdenCe, FK 501 Trough ,...... Levete, GeMnI 
ctwectertstlca, .nd OUtcome of the ..... an.a ~
PrIore.ty No PrIor 
0nIIt ~
No. patientS (%) 59(17.4%, 63(18.8%) 
FK 506 levels (ngImL) 
At start onset 1.4: 1.1 1.6:1.1 
At end onset 0.8: 0.7 0.9:0.7 
Median time of occumtnee (a 98 130 
afterOLTx) 
MedIan duration of onset (a) 168 159 
No. patients requiring dialylis 5 (8.5%) 10 (15.9%) 
outcome (no. patientS (%)) 
DeaIt1a during the onset 6 (10.2%) 8 (12.7%) 
Ongoing nephn:Jpalhy 32(54.2%) 35(55.5%) 
Complete AIClO'MrY 21 (35.8%) 20(31.8%, 
The 10 IIdIr* trill dIMIDIIed along iIIIIIlg 1iSjffK~ lIIagralliilg Irum 
eMyanMI wIIhcuINCIIMIY( ....... III!IhClbdCily) _ nat InCIudId (_....,. 
Eighteen patients required dialysis at some time after the 
first month. in 5 instances after initial recovery from an 
early onset nephropathy, and in the other 13 during a 
long-lasting nephropathy progressing from an early onset 
without recovery (persistent nephrotoxicity). The need for 
dialysis was associated with toxic FK 506 levels, and 
recovery from the episode appeared to be dose-dependent 
(Table 4). 
Of the 75 patients who required dialysis support, 51 
(69%) recovered and did not require long-term dialysis. 5 
were still on dialysis when the study was concluded in July 
1991, and 19 died. 
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T ... 4. InctdInce of ~ for DIalysis, FK 508 Trough 
PI...,. a..n.I8, G ...... Ch8nIctertsIIca and Outcome 
No. patients 
FK 506 Ievefs (nglmL) 
AI start of dialy8ia 
AI end of dialysia 
Median time at oce&mtnC8 
(days atter OLTx) 
Median duratiOn (d) 
outcome [no. patients (%)J 
Deaths on dialysis 
SilO on dialysis 
Complete rect1tIfKY 
Hypertension 
-
FK!08 
20(5.9%) 
6.4:: 4.9 
1.5: 1.2 
8 
20 
1 (5%) 
1 (5%) 
18(90%) 
OIlIer 
37 (10.9%) 
6.9:: 6.9 
2.3: 2.5 
9 
27 
14 (37.8%) 
1 (2.7%) 
22 (59.50/0) 
LaIIOnIeI 
18 (5.3%) 
4.1 :!: 4.1 
1.3:!: 1.2 
131 
29 
4 (22.2"10) 
3 (16.7%) 
11 (61.1%) 
Fourteen of the 370 patients were hypertensive before 
transplantation and were excluded from this analysis. A 
total of 122 patients. or 32.9% of the culled study popuia-
tion, developed new onset hypertension after transplanta-
tion (Table 5). The hypertension occurred at a median time 
of 52 days posttransplant and was transient in only 10.7%; 
84.5% started on therapy still require some form of anti-
hypertensive medication. while the remaining 4.9% died 
while hypertensive. Most of the hypertensive patients 
(63.2%) were treated with only one antihypertensive drug. 
In more than half of the cases, a clear association 
between a toxic FK 506 level and the hypertension could 
not be demonstrated; the mean FK 506 level at the 
diagnosis of hypertension was 1.78 ::!: 1.9S ng/mL. How-
ever, recovery, when it occurred, was associated with a 
reduction in the FK 506 dose. 
A comparison between the hypertensive and the nonby-
pertensive patients failed to show a significant difference in 
their steroid requirement at day 30 posttransplant, but a 
tendency for a higher steroid dosage at day ISO appeared to 
be present. suggesting a role for steroids in the pathogen-
esis of the hypertension. 
HyperIcalemia 
Hyperkalemia. which occurred in 239 patients (64.6%) 
(Table 5). was not associated with elevated plasma FK 506 
levels. Nevertheless, spontaneous recovery, which oc-
curred in 27% of the cases, was associated with a reduction 
in the FK 506 dose. The hyperkalemia generally was 
controUed easily. For patients who did not experience a 
spontaneoUS decline of the elevated potassium, a synthetic 
mineralocorticoid drug was prescribed. Such treatment 
was required in 46% of the affected population. 
Glucose Intolerance 
Of the 370 patients studied, 25 who were diabetic before 
their transplantation were excluded from the analysis. 
Glucose intolerance requiring insulin within 30 days was 
seen in 61 patients (17.7%) at a median time of 1 day. 
However. all were receiving TPN. Twenty-three of these 
patients recovered, 23 more (37.7%) developed pennanent 
diabetes mellitus. and 15 died while receiving insulin 
therapy (Table 5). 
Late onset diabetes occurred at a median of 152 days in 
18 (5.2%) of the 345 patients studied. The mean FK 506 
level at the onset of the late diabetes mellitus was 2.67 ::!: 
2.S2 ng/mL (Table 5). With an appropriate reduction in the 
FK 506 dose, the requirement for insulin therapy was 
reduced. Three of the IS patients required insulin treat-
ment temporarily. Of the remaining 15 patients, 4 died on 
insulin therapy, and 11 more are still insulin-dependent. 
Neurotoxicity 
Thirty-one (S.4%) (Table 5) of the patients had major 
neurological complications related to the use of FK 506: 
seizures (12 cases), delirium (11), dysarthria (5), and coma 
(4). These events tended to occur in the early posttrans-
plantation period after a median time of 10 days. The 
episodes were associated with toxic FK 506 levels, and 
Table 6. Inctdlla, FK 508 Trough ,..... LAMI6a, and OUtcome of NeulotDJdcHy, ""*11 ......... ~ ....... and 
GI ........... 
GUCOIeIl ...... 
NeuruDdcIy ~ HypeI.1IiaI1 Early I..-
No. patients 31 (S.4%) 238(84.6%) 122(32.9%) 61 (17.7%) 18 (5.20/0) 
FK 506 levels (ngtmL) 
Al start 3.3:: 3.4 1.6: 1.4 1.S: 1.9 4.5:4.1 2.7: 2.8 
Aland 1.9: 3.1 0.7:0.5 0.9:0.7 1.9: 3.1 1.8: 2.5 
MedIan time of oc:currence (d) 10 23 52 152 
outcome [no. patients (%») 
DeaIh during episode 1 (3.2%) 6 (2.5%) 6(4.9%) 15(24.8%) 4 (22.2%) 
SIll preeent 1 (3.2%) 188(70.7%) 103 (84.4%) 23 (37.7%) 11 (81.1%) 
Complete I8CIMrY 29(93.6%) 84(28.8%) 13(10.7%) 23(37.7%) 3(18.7%) 
ADVERSE EFFECTS OF FK 506 
responded to dose reduction in all but one case (Table 5). 
The exceptional patient. a previously reponed 38-year-old 
woman4 developed expressive dysphasia at the same time 
that magnetic resonance (MR) imaging demonstrated areas 
of demyelinization in her pons. She had a slow improve-
ment in her speech over a 9O-day period. but subsequently, 
she developed a severe depression with recurrence of 
dysphasia and ataxia. The clinical evaluation of her neu-
rological symptoms was complicated by the pre-existing 
presence of both alcohof and drug abuse. A recent MR 
scan of her head has demonstrated diffuse cortical atrophy 
which was the same as at the first examination. 
DISCUSSION 
Within a few weeks after beginning the first clinical trials 
with FK 506. the similarity of its side effects to those of 
Cy A was identified. 1-9 The principal undesirable effects of 
both drugs were nephrotoxicity. diabetogenicity, and neu-
rotoxicity. Although both agents promoted liver growth 
(the regeneration after partial hepatectomyl$.16) and pre-
vented the hepatic atrophy of Eck fistula. '7•18 FK 506 has 
not caused the somatic growth complications of gingival 
hyperplasia. hirsutism. and coursening of facial features 
that have been seen with CyA. FK 506 also had a smaller 
hypercholesterolemia effect than CyA and appeared to 
have a lesser tendency for the development of hyperten-
sion.4•19.2O 
Because FK 506 and Cy A are chemically unrelated. and 
have different cytosolic binding sites. the similarities in 
their actions and side reactions were puzzling at first. 
When it was discovered that both binding sites were rich in 
the enzyme, peptidyl-prolyl isomerase (PPIase), which 
facilitates protein folding,'.2 an inhibitory action on these 
drugs on PPIase was suggested at first to rationalize the 
commonality of their action.J •4•13 However. the explana-
tion for the shared pleiotropic effects of these drugs has 
been more complex. It is realized now that both FK 506 
and Cy A are "pro-drugs" that are pharmacologically inert 
until they complex with their binding sites. Apparently. 
modulation by the drug-immunophilin complex occurs at a 
common target. the protein phosphatase calcineurin.ll 
These developments and the results from sophisticated 
drug-modeling experiments have raised the possibility that 
the. principal toxicities of these two drugs may be immu-
tably linked to their desired immunosuppression. With 
either drug, the severity of the side effects is dose related. 
Because the quantities of FK 506 given to the patients in 
this study were two or three times the currently prescribed 
doses, it was not surprising that there was a high incidence 
of adverse reaction. In spite of this, and the acquisition of 
experience during a learning curve, the results in this 
consecutive series of 370 patients, with a large represen-
tation of higb-risk candidates, was better than in our 
historical experience with Cy A.ll This superiority also 
was noted in a subsequent randomized trial13 in which the 
633 
usefulness of FK 506 was retained with the lower induction 
doses. 
Nevertheless, nephrotoxicity is the principal dose-limit-
ing factor in the use of FK 506 as it was with its predeces-
sor, CyA. Prior to the utilization of pharmacologic moni-
toring techniques for both Cy A and FK 506, renal 
dysfunction often was used as a guideline to effective 
dosing. The use of trough drug levels has allowed an easier 
and safer use of these drugs, but there still is a variability 
factor in that some patients manifest toxicity at "therapeu-
tic" levels in the range of 1 ng/mL while others do not 
show side effects at "excessive" levels far above this. 
The problem would be less sinister if simple dose 
adjustments could eliminate the nephropathic liability. 
CyA-related acute nephrotoxicity after liver transplanta-
tion has been reported in up to 40% of casesZ4-26 and, in 
long-term follow-up studies, there is evidence that Cy A 
can result in chronic renal failure in more than 70% of 
patients.27.28 It would not be hard to extrapolate these 
findings to those reported herein with FK 506 unless 
appropriate dose adjustments are made for· subsequent 
cases. 
The mechanism of Cy A nephrotoxicity has not been 
completely clarified, but a reduction of blood flow due to 
vasoconstriction. and then a consequent reduction of the 
glomerular filtration rate (GFR), has been demonstrated.l4 
When chronic nephrotoxicity supervenes in CyA-treated 
patients, the vascular endothelial changes and chnxUc 
structural interstitial alterations do not respond to dose 
reductions or even complete withdrawal.29 It is unrealistic 
to believe that these same lessons do not pertain to FK 
506. Therefore, prophylaxis must be a foremost concern in 
treatment strategies with FK 506 including an effort to use 
lower doses, avoid high trough levels, and incorporate 
other nonnephrotoxic agents into drug cocktails that will 
reduce the need for high-dose FK 506 to achieve the 
desired immunosuppression. 
As these strategies are evolved, it must be borne in mind 
that there are pharmacokinetic differences between FK 
506 and Cy A. Both agents are virtually completely metab-
olized in the liver, but it has happened that the risk from 
astronomical blood levels and clinical toxicity is greater 
under FK 506 than CyA in patients who do not achieve 
good hepatic function postliver transplantation. Such er· 
rors can be avoided by close monitoring of serum plasma 
or blood FK 506 levels. 
Other differences between the two drugs also should be 
recognized. The oral absorption of FK 506, unlike Cy A, is 
not dependent upon bile and is also much better main-
tained in the face of diarrhea and certain malabsorption 
disorders.30 These characteristics make it particularly ad-
vantageOus for transplantation of all of the gastrointestinal 
organs. 
We have reported elsewhere the incidence of nervous 
system complications.9.IO.l1 and of diabetes mellitus.4,$.7.8 
The incidence of these complications was less than neph-
rotoxicity, but was similarly related to elevations in the 
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monitored plasma FK 506 level. The only parameters 
studied that were not seemingly correlated with the FK 506 
trough levels were hyperkalemia and hypenension. but 
even these complications were responsive to dose reduc-
tion and easily controlled with specific medications. 
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